ProCE Banner Activity

CME

Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2022

Conference Coverage
Text Module

Expert faculty review and share their insights and perspectives on key studies in the management of lung cancer presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: September 01, 2022

Expiration: August 31, 2023

No longer available for credit.

Share

Faculty

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with lung cancer

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lung cancer
  • Identify subpopulations of patients with lung cancer most likely to benefit from a specific treatment plan based on predictive biomarkers
  • Evaluate new data on novel agents and therapeutic approaches for patients with lung cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Stephen Liu, MD: consultant/advisor: AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher (paid to institution): Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data and safety monitoring board: Candel Therapeutics.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, Blueprint, C4 Therapeutics, Cullinan, Daiichi Sankyo, Janssen, Jazz, Lilly, Takeda; researcher: AbbVie, AstraZeneca, Blueprint, Cullinan, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro/GlaxoSmithKline.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant financial relationships to disclose.

Brian Purves, PharmD, MBA

Brian Purves has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 01, 2022, through August 31, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer